Open access · CC-BY
via OpenAlex
Dasatinib and Quercetin Combination Increased Kidney Damage in Acute Folic Acid-Induced Experimental Nephropathy
Antonio Battaglia-Vieni, Vanessa A Marchant, Lucía Tejedor-Santamaria, Cristina García‐Caballero, Elena Flores-Salguero, María Piedad Ruiz‐Torres, Sandra Rayego‐Mateos, Ana Belen Sanz, Alberto Ortíz, Marta Ruiz‐Ortega
Pharmaceuticals · 2025 · ▲ 11 citations
Abstract
Background/Objectives: Acute kidney injury (AKI) remains an unsolved medical problem due to the lack of effective treatments, high mortality, and increased susceptibility to progression to chronic kidney disease (CKD), especially in the elderly. Cellular senescence(definition) has been described in AKI, CKD, and aging and has been proposed as a promising therapeutic target. The senolytic drug combination of dasatinib plus quercetin (D&Q) is beneficial in some pathological conditions, including experimental CKD, but there are no data for AKI. Methods: The effect of D&Q combination was tested in folic acid-induced nephrotoxicity (FAN-AKI), a murine AKI model. Results: D&Q pretreatment did not prevent renal dysfunction in the acute phase of FAN-AKI, as determined by serum creatinine and BUN levels at 48 h. Moreover, gene expression of the kidney damage biomarkers Lcn2 and Havcr1, the Cdkn1a gene, which encodes p21, and some genes encoding components of the senescent cell secretome were significantly increased in response to D&Q treatment. The number of senescent p21-positive cells in injured kidneys was similar in untreated or D&Q-treated FAN mice. In addition, D&Q did not prevent the downregulation of the antiaging factor Klotho in damaged kidneys. Conclusions: D&Q treatment was not protective in FAN-AKI, exacerbating some deleterious responses. These results suggest caution when exploring the clinical translation of D&Q senolytic activity.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/ph18060822
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Battaglia-Vieni, A., Marchant, V.A., Tejedor-Santamaria, L., García‐Caballero, C., Flores-Salguero, E., Ruiz‐Torres, M.P., Rayego‐Mateos, S., Sanz, A.B., Ortíz, A., & Ruiz‐Ortega, M. (2025). Dasatinib and Quercetin Combination Increased Kidney Damage in Acute Folic Acid-Induced Experimental Nephropathy. <em>Pharmaceuticals</em>. https://doi.org/10.3390/ph18060822
Vancouver
Battaglia-Vieni A, Marchant VA, Tejedor-Santamaria L, García‐Caballero C, Flores-Salguero E, Ruiz‐Torres MP, et al. Dasatinib and Quercetin Combination Increased Kidney Damage in Acute Folic Acid-Induced Experimental Nephropathy. Pharmaceuticals. 2025. doi:10.3390/ph18060822.
BibTeX
@article{antonio2025Dasati,
title = {Dasatinib and Quercetin Combination Increased Kidney Damage in Acute Folic Acid-Induced Experimental Nephropathy},
author = {Antonio Battaglia-Vieni and Vanessa A Marchant and Lucía Tejedor-Santamaria and Cristina García‐Caballero and Elena Flores-Salguero and María Piedad Ruiz‐Torres and Sandra Rayego‐Mateos and Ana Belen Sanz and Alberto Ortíz and Marta Ruiz‐Ortega},
journal = {Pharmaceuticals},
year = {2025},
doi = {10.3390/ph18060822},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Preprints.org 2025
Preprint · CC-BY
Dasatinib and Quercetin Treatment Increased Kidney Damage in Acute Folic Acid-Induced Experimental Nephropathy
Journal of the American Society of Nephrology 2025
Citation only
Dasatinib and Quercetin Combination Increases Kidney Damage in Acute Folic Acid-Induced Experimental Nephropathy
The FASEB Journal 2015
Citation only
Klotho Deficiency Causes Kidney Fibrosis via Activation of the Notch2 Signaling pathway
Libyan Journal of Medical Research 2025
Open access · CC-BY
Klotho gene transfection into mesenchymal stem cells as a potential therapy for kidney disease
Nephrology Dialysis Transplantation 2025
Open access · OA
#2529 Nanoparticle-mediated Klotho gene therapy prevents kidney disease progression via PPARα pathway
Frontiers in Medicine 2023
Open access · CC-BY